Surface Oncology, Inc. (NasdaqGM: SURF) Loss Submission Form

Kuznicki Law is investigating the proposed sale of Surface Oncology, Inc. (NasdaqGM: SURF) to Coherus BioSciences, Inc. (NasdaqGM: CHRS).  Under the terms of the proposed transaction, Coherus will issue shares of its common stock at a price of $5.2831 per share to acquire all outstanding shares of Surface stock. Surface shareholders will also receive certain Contingent Value Rights as part of the agreement. Kuznicki Law is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.